Sirkka Networks Secures £21.8k Capital Injection to Advance Mobile Health Platform

Sirkka Networks Limited, operating as Sirkka Health, a London-based provider of an integrated medical assistance SmartPlatform, has recently secured a capital injection of £21.8k. The funding round, with an allotment date of 30 March 2026 and a filing date of 17 April 2026, marks a continued investment in the company's mission to enhance access to mobile pathology and imaging scan services across the UK.

Founded on 11 February 2014, Sirkka Health addresses the growing need for convenient and accessible healthcare diagnostics. The company develops user-friendly software and cultivates a nationwide network of nurses to offer mobile blood tests and facilitate imaging scan services directly to individuals at their homes, workplaces, or other preferred locations. This approach aims to streamline the diagnostic process for both healthcare providers and their customers, automating the entire pathway from appointment booking and test delivery to the release of risk-factor adjusted results. Sirkka Health's software solutions can be white-labelled or easily integrated, supporting end-to-end customer pathway management for both individual and group mobile tests.

While the specific valuation for this recent £21.8k funding round has not been disclosed, this capital injection underscores ongoing support for Sirkka Health's operational expansion and technological development. The company's latest available accounts indicate four employees, though its LinkedIn profile suggests a larger team of 17 professionals, reflecting potential growth in its workforce. Sirkka Health has established notable partnerships, including recognition by Bupa insurance for its pathology tests and serving as the Official Health Partner for British Bobsleigh & Skeleton.

The investment in Sirkka Health aligns with broader positive trends within the UK's HealthTech and digital health sectors. The UK HealthTech market is experiencing a period of significant growth and investment, driven by technological advancements and evolving healthcare needs. In Q1 2025, UK HealthTech and life sciences startups collectively raised £1.4 billion in venture capital, marking an 8% increase compared to Q1 2024 and positioning health as the most funded sector in the UK by a significant margin. The UK digital health market alone was valued at approximately £12.5 billion (USD 15.46 billion) in 2025 and is projected to reach approximately £35.6 billion (USD 43.98 billion) by 2031, demonstrating a robust compound annual growth rate of 19.10% during this period.

Key drivers for this growth include sustained investment by the National Health Service (NHS) in electronic patient records, the expansion of virtual ward capacity, the increasing user base of the NHS App, and an emerging wave of AI-enabled analytics designed to optimise care pathways and reduce administrative burdens. The diagnostics and decision support segment, which Sirkka Health operates within, is specifically forecast to expand at a CAGR of 21.28% through 2031. The broader UK medical technology sector generates an annual turnover of approximately £29 billion (USD 35.8 billion) and supports over 138,000 jobs. Within this, the diagnostic 'wholesale' market is valued at £9.3 billion, with the NHS accounting for £8.4 billion, while the 'retail' market for private diagnostic tests stands at £1.4 billion.

There is a clear strategic push within the UK healthcare system to shift care delivery beyond traditional hospital settings, with a focus on community-based services and technologies that facilitate out-of-hospital monitoring, treatment, and patient engagement. Government initiatives and funding play a crucial role in this transformation, with the NHS Long Term Plan outlining substantial investments aimed at enhancing digital infrastructure and services. The UK government has expressed aspirations to achieve digitally supported care services for 75% of the population by 2023, indicating a strong commitment to integrating new technologies into the health sector. This supportive environment, coupled with increasing patient demand for convenient diagnostic solutions, creates a fertile ground for companies like Sirkka Health.

While the recent funding round for Sirkka Networks Limited is modest in size, it contributes to the ongoing development of a company positioned within a rapidly expanding and strategically important segment of the UK's healthcare landscape. As the demand for accessible and efficient diagnostic services continues to grow, Sirkka Health's integrated SmartPlatform and mobile service network are poised to play a role in the evolving delivery of healthcare.